Skip to main content

Drug Interactions between eptifibatide and tenecteplase

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

eptifibatide tenecteplase

Applies to: eptifibatide and tenecteplase

MONITOR CLOSELY: The intended and unintended effects of glycoprotein IIb/IIIa inhibitors and thrombolytic agents are additive, such that there is an increased frequency of major bleeding complications, including intracranial hemorrhage, retroperitoneal bleeding, spontaneous gastrointestinal (GI) and genitourinary (GU) bleeding among patients receiving both agents compared with the risk associated with the use of either agent alone. In one clinical trial, the risk of bleeding increased by twofold when abciximab was given after full-dose thrombolytics, while other studies have not reported an increased risk. Fatalities have occurred. Arterial puncture sites may be most problematic.

MANAGEMENT: It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications. The successful use of combination therapy with glycoprotein IIb/IIIa inhibitors and reduced doses of thrombolytics has been reported in clinical trials. Patients should be closely monitored for signs of bleeding, especially at arterial puncture sites. Thrombolytic and/or glycoprotein inhibitor therapy should be discontinued immediately if serious or uncontrollable bleeding occurs.

References

  1. (2001) "Product Information. Integrilin (eptifibatide)." Schering Corporation
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  3. Cerner Multum, Inc. "Australian Product Information."
  4. Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
View all 4 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer